Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 9 de 9
Filter
Add more filters










Database
Publication year range
1.
J Autoimmun ; 146: 103242, 2024 Jun.
Article in English | MEDLINE | ID: mdl-38761452

ABSTRACT

OBJECTIVE: To assess the prognosis and outcome of patients with isolated carotid vasculitis. METHODS: We performed a retrospective multicenter study of 36 patients (median age at diagnosis was 37 [IQR 27-45] years and 11 [31 %] patients were men) with initial presentation as isolated carotid vasculitis. Study endpoints included vascular complications, relapses, and progression to large vessel vasculitis (i.e. Giant cell arteritis or Takayasu). RESULTS: The most frequent involvement was the left internal carotid artery (39 %), and 81 % had stenosis. After a median follow-up of 32 months [IQR 12-96], 21 (58 %) patients had a vascular event, including 31 % of new onset vascular lesions and 25 % of stroke/transient ischemic attack. Patients with stroke had less carotidynia at diagnosis (33 % vs 74 %, p = 0.046), higher significant carotid stenosis (i.e. > 50 %) (89 % vs. 30 %, p = 0.026) and higher severe carotid stenosis (i.e. >70 %) (67 % vs 19 %, p = 0.012), compared to those without stroke. Twenty (52 %) patients experienced relapses. High CRP at diagnosis was associated with relapses (p = 0.022). At the end of follow-up, 21 (58 %) patients were classified as having Takayasu arteritis, 13 (36 %) as isolated carotid vasculitis, and two (6 %) as giant cell arteritis. CONCLUSION: Carotid vasculitis may occur as a topographically limited lesion and is associated with significant rate of vascular complications.


Subject(s)
Giant Cell Arteritis , Humans , Male , Female , Prognosis , Middle Aged , Retrospective Studies , Adult , Giant Cell Arteritis/diagnosis , Takayasu Arteritis/diagnosis , Recurrence , Vasculitis/diagnosis , Follow-Up Studies , Stroke/etiology , Stroke/diagnosis , Carotid Stenosis/diagnosis , Disease Progression
2.
Rev Mal Respir ; 40(3): 254-264, 2023 Mar.
Article in French | MEDLINE | ID: mdl-36740495

ABSTRACT

Ehlers-Danlos syndromes (EDS) represent a heterogeneous group of heritable connective tissue disorders characterized by the clinical "triad" consisting in joint hypermobility, skin hyperextensibility and tissue fragility. Respiratory manifestations associated with EDS are frequent and variable. They vary mainly according to the type of EDS. In hypermobile and classical EDS, the most frequent non-vascular types, dyspnea is a common symptom. Its etiologies are wide-ranging and can coexist in the same patient: asthma, respiratory muscle weakness, chest wall abnormalities, upper and lower airway collapse. The prevalence of obstructive sleep apnea syndrome in nvEDS is high. Identification of the relevant dyspnea mechanism is essential to providing appropriate therapeutic measures. In vascular EDS (vEDS), the main pulmonary complications are pneumothorax, hemothorax and hemoptysis. As they frequently precede the diagnosis of vEDS by several years, it is imperative to raise the possibility of vEDS in a young patient with spontaneous pneumothorax or hemothorax. The presence of suggestive computed tomography parenchymal abnormalities (emphysema, clusters of calcified nodules, cavitated nodule) can be an aid to diagnosis. Treatment is based on the usual approaches, which must be carried out with caution by an experienced operator fully informed of the diagnosis. Better knowledge of respiratory manifestations of EDS by the pneumological community would improve patient care and pave the way for further research.


Subject(s)
Ehlers-Danlos Syndrome, Type IV , Ehlers-Danlos Syndrome , Pneumothorax , Skin Abnormalities , Humans , Hemothorax/complications , Ehlers-Danlos Syndrome/complications , Ehlers-Danlos Syndrome/diagnosis , Skin Abnormalities/complications , Pneumothorax/diagnosis , Pneumothorax/epidemiology , Pneumothorax/etiology
3.
Rev Mal Respir ; 39(6): 523-533, 2022 Jun.
Article in French | MEDLINE | ID: mdl-35659162

ABSTRACT

Behcet's disease (BD) is a multisystemic vasculitis involving arteries and veins of all sizes. While joint and dermatological manifestations are the most common features of BD and are associated with a good prognosis; vascular involvement, remains the principal cause of death. Arterial manifestations occur in 5-10% of cases and manifest as occlusion/thrombosis or aneurysms. Arterial aneurysms are likely multiple and the most common sites are pulmonary arteries, aorta and arteries of lower limbs. Parenchymal involvement is less frequent and may manifest as consolidation or nodules, which may evolve to excavation. Aneurysms may occur at the sites of arterial puncture; then, non-traumatic techniques are favored. Patients with arterial manifestations may present with fever and increased inflammatory markers. Artery damage is rare, serious, and may result in massive hemoptysis. The prognosis of pulmonary artery aneurysms is severe (mortality estimated up to 26%) but has been improved by earlier diagnosis and the introduction of immunosuppressants. Treatment of severe arterial manifestations is based on high-dose corticosteroids along with cyclophosphamide or anti-TNF antagonists. Anticoagulation could be added to immunosuppressants in case of venous thrombosis if a coexisting pulmonary aneurysm is ruled out. Endovascular treatment should be performed in case of severe symptomatic pulmonary aneurysms, along with an adequate medical management. Long-term maintenance therapy of these severe forms is of paramount importance because of relapse risk (40% at five years).


Subject(s)
Aneurysm , Behcet Syndrome , Aneurysm/complications , Aneurysm/etiology , Behcet Syndrome/complications , Behcet Syndrome/diagnosis , Behcet Syndrome/drug therapy , Humans , Immunosuppressive Agents/therapeutic use , Pulmonary Artery , Tumor Necrosis Factor Inhibitors
4.
Infect Dis Now ; 51(4): 368-373, 2021 Jun.
Article in English | MEDLINE | ID: mdl-33495763

ABSTRACT

OBJECTIVE: To describe clinical, biological, radiological presentation and W4 status in COVID-19 elderly patients. PATIENTS AND METHODS: All patients ≥ 70 years with confirmed SARS-CoV-2 infection and hospitalized in the Infectious Diseases department of the Pitié-Salpêtrière hospital, Paris, France, from March 1st to April 15th 2020 were included. The primary outcome was death four weeks after hospital admission. Data on demographics, clinical features, laboratory tests, CT-scan findings, therapeutic management and complications were collected. RESULTS: All in all, 100 patients were analyzed, including 49 patients ≥ 80 years. Seventy percent had ≥2 comorbidities. Respiratory features were often severe as 48% needed oxygen support upon admission. Twenty-eight out of 43 patients (65%) with a CT-scan had mild to severe parenchymal impairment, and 38/43 (88%) had bilateral impairment. Thirty-two patients presented respiratory distress requiring oxygen support ≥ 6 liters/minute. Twenty-four deaths occurred, including 21 during hospitalization in our unit, 2 among the 8 patients transferred to ICU, and one at home after discharge from hospital, leading to a global mortality rate of 24% at W4. Age, acute renal failure and respiratory distress were associated with mortality at W4. CONCLUSION: A substantial proportion of elderly COVID-19 patients with several comorbidities and severe clinical features survived, a finding that could provide arguments against transferring the most fragile patients to ICU.


Subject(s)
COVID-19/diagnosis , Aged , Aged, 80 and over , COVID-19/diagnostic imaging , COVID-19/mortality , Female , Hospitalization , Humans , Male , Prognosis , Retrospective Studies , Time Factors
5.
Clin Immunol ; 197: 54-59, 2018 12.
Article in English | MEDLINE | ID: mdl-30125675

ABSTRACT

OBJECTIVE: To describe the outcome and tolerance in patients treated with anti-TNFα in severe and refractory major vessel disease in Behçet's disease (BD). METHODS: A multicenter study evaluating 18 refractory BD patients with major vessel involvement [pulmonary artery (n = 4), aorta (n = 4) or peripheral artery aneurysm (n = 1) and/or pulmonary artery (n = 7), inferior vena cava (n = 5), or intra-cardiac (n = 3) thrombosis or Budd Chiari Syndrome (n = 2)] treated with anti-TNFα agents. RESULTS: Vascular remission was achieved in 16 (89%) patients. The 9 months risk of relapse was significantly higher with conventional immunosuppressants used prior anti-TNFα agents as compared to anti-TNFα therapy [OR = 8.7 (1.42-62.6), p = 0.03]. The median daily dose of corticosteroids significantly decreased at 12 months. Side effects included infection (n = 4) and pulmonary edema (n = 1). CONCLUSION: TNFα-antagonists are safe and might be associated with a decreased risk of relapse at 9 months compared to conventional immunosuppressants in BD patients with major vessels disease.


Subject(s)
Adalimumab/therapeutic use , Antirheumatic Agents/therapeutic use , Behcet Syndrome/drug therapy , Infliximab/therapeutic use , Thrombosis/physiopathology , Adult , Aortic Diseases/etiology , Aortic Diseases/physiopathology , Behcet Syndrome/complications , Behcet Syndrome/physiopathology , Budd-Chiari Syndrome/etiology , Budd-Chiari Syndrome/physiopathology , Female , Heart Diseases/etiology , Heart Diseases/physiopathology , Humans , Immunosuppressive Agents/therapeutic use , Infections , Logistic Models , Male , Middle Aged , Pulmonary Artery/physiopathology , Pulmonary Edema , Recurrence , Remission Induction , Retrospective Studies , Severity of Illness Index , Thrombosis/etiology , Tumor Necrosis Factor-alpha/antagonists & inhibitors , Vascular Diseases/etiology , Vascular Diseases/physiopathology , Vena Cava, Inferior/physiopathology , Young Adult
9.
Sarcoidosis Vasc Diffuse Lung Dis ; 32(3): 188-93, 2015 Sep 14.
Article in English | MEDLINE | ID: mdl-26422562

ABSTRACT

BACKGROUND: Core-needle biopsy guided by ultrasound can be performed for investigating peripheral lymph node (PLN). The aim of this study was to determine the efficacy of this technique in sarcoidosis. METHODS: Retrospective review of files of all patients in the database of the radiology department of Avicenne university hospital who underwent PLN biopsies guided by ultrasound from January 2008 to June 2011 (n=292). Cases with either granulomas at histology with the procedure or with a final diagnosis of sarcoidosis were included in the study. RESULTS: The histological specimens were adequate in 282 out of 292 cases (96%) showing non-caseating granulomas in 22 cases (n=20 patients with a final diagnosis of sarcoidosis and n=2 patients with tuberculosis). After reviewing clinical files of the 282 patient, 22 were confirmed to have sarcoidosis, at initial presentation (n=19) or later during flare-up or relapse (n=3) with only 2 patients having no granuloma on PLN biopsy. PLN were palpable in 18 cases and only detected by (18F)FDG-PET/CT showing increased PLN uptake in 4 cases. The sensitivity and specificity of adequate biopsy were 91 and 99% and the positive and negative predictive values were 91 and 99%, respectively. CONCLUSION: Core-needle biopsy guided by ultrasound has a high efficacy for evidencing granulomas in sarcoidosis patients with PLN involvement either clinically palpable or in the presence of (18F)FDG-PET/CT uptake.


Subject(s)
Biopsy, Large-Core Needle , Granuloma/pathology , Lymph Nodes/pathology , Sarcoidosis/pathology , Ultrasonography, Interventional , Adult , Aged , Databases, Factual , Female , Fluorodeoxyglucose F18 , France , Granuloma/diagnostic imaging , Humans , Lymph Nodes/diagnostic imaging , Male , Middle Aged , Multimodal Imaging , Palpation , Positron-Emission Tomography , Predictive Value of Tests , Radiopharmaceuticals , Retrospective Studies , Sarcoidosis/diagnostic imaging , Tomography, X-Ray Computed , Young Adult
SELECTION OF CITATIONS
SEARCH DETAIL
...